Health
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
In a sterile Bristol Myers Squibb lab about an hour north of Boston, scientists in scrubs and hairnets transfer living cells to a 2,000-liter stainless steel bioreactor that grows them for weeks. The goal is to produce proteins that are genetically engineered to attack cells that cause disease.
Tiny variations in heat, light or pH level can stop the cells from growing, causing drug shortages that endanger patients. Typically scientists would have to wait to see what went wrong during that fragile process, but now artificial intelligence is used to carefully monitor important variables — such as temperature and oxygen levels — and alert technicians if there are problems.
Every year the World Economic Forum and McKinsey recognize manufacturers that are on the cutting edge of technology, including artificial intelligence. This year, the Bristol Myers Squibb facility in Devens, Mass., was the only manufacturer in the United States that made the list of 23.
While American companies typically lead in artificial intelligence research and capital investment, U.S. manufacturers often struggle to translate those breakthroughs into productivity gains on the factory floor.
Of the 223 factories that have made the World Economic Forum’s Global Lighthouse Network list since 2018, 14 have been in the United States, while 99 are in China. Of the American ones, four are in the pharmaceutical and life sciences sector.
“China is scaling faster,” said Rahul Shahani, a partner at McKinsey who works with the World Economic Forum on the initiative. He added, “They have technologists in the factories — hundreds of them — while in the U.S. we’re competing for that same talent with Silicon Valley.”
Large American pharmaceutical companies have been a rare bright spot in the use of A.I. Many drugmakers, including Pfizer and Eli Lilly, are investing billions in A.I. and related technologies to accelerate drug discovery and streamline manufacturing. The trend coincides with President Trump’s demands that drugmakers produce more drugs on U.S. soil.
Scientists at the Devens facility use artificial intelligence to discover molecules that can target cancer and other diseases with greater precision. A.I. can comb through data sets from past experiments to identify possibilities that a human might not have considered. Researchers then test those molecules in the virtual world — a process referred to as “in silico.” Only the most promising are tested in a physical laboratory. The company can run multiple “in silico” experiments at a time.
“Drug discovery and bio-manufacturing are definitely areas where A.I. can have the most impact,” said Kyle Chan, a fellow at the Brookings Institution’s John L. Thornton China Center. “These are areas where A.I. has some of the largest advantages over previous approaches given the need to process and synthesize large, complex data sets.”
Still, there’s no guarantee that technological advantages will instantly equate to benefits for patients. The history of drug development is filled with failures, and it is unknown whether molecules identified by A.I. will pass muster in clinical trials.
The Bristol Myers Squibb facility sits on an 89-acre campus where buildings are decorated with portraits of cancer survivors..
Previously, scientists and technicians were never sure why some batches of cells produced a large amount of proteins, while others failed completely. But now A.I. uses information from past batches to identify what variables need to change. For example, if oxygen levels are lower than previous batches, the system will suggest that oxygen be added. If the pH levels are higher than previous batches, it will recommend a fix. It also makes suggestions about the best time to harvest the cells.
These innovations have boosted the volume of drugs produced for clinical trials and commercial use at the facility by about 40 percent, according to a company spokeswoman.
“We are able to now intervene in the batches during the manufacturing process and not have to wait until we get to the end,” said Karin Shanahan, executive vice president, chief supply chain and operations officer for the company.
These innovations have helped stabilize production of Orencia, a drug that treats autoimmune conditions such as rheumatoid arthritis using cells that are extremely difficult to grow. In 2024, manufacturing challenges resulted in a shortage in some parts of the world.
The company is just beginning to use A.I. in its manufacturing process of another drug, Breyanzi, which turns a cancer patient’s own white blood cells into a personalized therapy. Currently, the Devens plant is authorized by the Food and Drug Administration to produce treatments for just 12 patients at a time.
Ms. Shanahan said she hoped that eventually A.I. would increase production of the treatment, often viewed as a last resort for people with blood cancers such as leukemia.
Bristol Myers Squibb has embarked on a series of cost-cutting measures as the key patent for its cancer drug Opdivo expires in 2028. The drug, which uses proteins that have been genetically engineered to target cancer cells, generated more than $10 billion of the company’s $48 billion in revenue last year.
The company is trimming $2 billion in costs by the end of 2027 in addition to $1.5 billion in cuts announced in 2024. More than 1,000 positions are being eliminated, many of them at a research facility in Lawrenceville, N.J., heightening anxiety about A.I.’s taking jobs away in the sector.
At the Semafor World Economy summit last month, Bristol Myers Squibb’s chief executive, Chris Boerner, said the company had a responsibility to use A.I. to further its mission but acknowledged that it could adversely affect some employees.
“We are engaging with those employees to make them more marketable around this technology — with the company or elsewhere,” he said.
The facility in Devens, which was completed in 2009 at a cost of $750 million, wasn’t designed with A.I. in mind. As recently as 2020, employees used Excel spreadsheets for some tasks. Batch records that document every step of production were filled out by hand. But in recent years, the company has prioritized digitizing and automating its processes.
“We needed to make sure that we could formulate our products faster, that we could commercially scale them faster,” Ms. Shanahan said. “And so that’s really what forced us to start to go down that path.”
Overall the company aims to cut the time it takes to bring a drug to market to about six years, from nine, she said.
Other factories that received recognition from the World Economic Forum this year included Yueda Textile in Yancheng, China, which collects sensor data to detect machine maintenance issues before they occur, reducing costs; and Midea, a manufacturer of microwaves and air-conditioners in Thailand that uses A.I. to investigate customer complaints, generating recommendations for corrective action that cut resolution time from months to days.
Health
AI-designed ‘universal vaccine’ passes first human clinical trial, could prevent future pandemics
NEWYou can now listen to Fox News articles!
A vaccine created using artificial intelligence that could potentially provide broader protection against multiple coronaviruses and help prepare for future outbreaks has passed its first human clinical trial.
Researchers from the Universities of Cambridge and Southampton developed a “universal vaccine” designed to protect against multiple Sarbeco coronaviruses, which the university explained in a news release is “the large group of viruses that occur in nature, including SARS-CoV-2, which caused the COVID pandemic.”
CLICK HERE FOR MORE LIFESTYLE STORIES
Traditional vaccines must constantly be updated as viruses mutate, and the process is “like a dog chasing its tail,” said University of Southampton professor Saul Faust, the trial’s chief investigator.
“Viruses like Influenza, coronaviruses and the Ebola group are evolving continuously, and by the time vaccines are rolled out, they may be poorly matched — the current ‘reactive’ vaccine system struggles to keep pace,” Faust said.
Researchers have developed a vaccine using AI that has proven to be promising in “future-proofing” people against mutating infections. (iStock)
An antigen is the active ingredient in a vaccine meant to trigger an immune-system response and fight off infection. According to the release, the university scientists logged all the available genetic sequence data for Sarbeco coronaviruses and used AI used to design a “super-antigen” that contains the antigen features “common to this whole group of viruses – including ones that haven’t emerged yet.”
The trial of the vaccine proved safe and triggered an immune response in 39 healthy volunteers, marking “the first time that a vaccine whose active component was designed entirely by computer simulations has been tested in humans,” the release said.
The trial vaccine was administered through a micro-fluid jet that delivers the immunization through the skin using a tiny, high-pressure stream of liquid and does not require a needle. The researchers said this method could make it “faster and easier to carry out in large numbers of people.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“This new class of universal vaccines are future-proofed,” Faust said. “They not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans. If we can develop and clinically advance this new class of vaccines before a virus outbreak begins, millions of lives could be saved, lockdowns avoided and the economy preserved.”
A new vaccine has been proven safe and capable of triggering immune responses against coronavirus in a limited human trial. (iStock)
Some experts have raised broad concerns about using AI in medicine, primarily when it comes to making clinical decisions, not developing vaccines. Certain groups of people may be underrepresented in the data AI relies on, resulting in biased outcomes, some said.
AI also sometimes produces erroneous information, called “hallucinations,” and determining who is liable for medical failings in such situations is a complex matter.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Others have expressed concern over patient privacy, as well as the need for human judgment that takes into account the scope of a patient’s health history, rather than a single dataset.
While traditional vaccines are reactive, a new AI-designed vaccine aims to protect against future coronavirus threats. (iStock)
The universal-vaccine researchers said that a larger trial involving “a wider and more diverse population” is needed. They published their findings in Journal of Infection.
NEWYou can now listen to Fox News articles!
Former professional wrestler and actor Tyler Mane announced he has been diagnosed with breast cancer.
Known for his roles in “X-Men” and “Halloween,” Mane shared the news publicly to help raise awareness about a condition that is frequently overlooked in men.
“I have some bad news. I start chemo today,” Mane stated in a video posted to his social media channels. “One in 750 men will be diagnosed with breast cancer in their lifetime, and I’m one of them.”
CANCER SURVIVORS SAW MAJOR IMPROVEMENTS IN SLEEP AND WELL-BEING WITH ONE WEEKLY PRACTICE
Because breast cancer is predominantly associated with women, many men are unaware that they are also at risk. However, according to Mayo Clinic, everyone is born with a small amount of breast tissue.
While women go on to develop more of this tissue during puberty, the biological foundation for the disease exists in everyone.
Known for his roles in X-Men and Halloween, Mane shared the news publicly to help raise awareness about a condition that is frequently overlooked in men. (Bobby Bank/Getty Images)
The most common symptom of male breast cancer is a hard, painless lump located directly behind or near the nipple, according to experts. Other signs can include skin dimpling, nipple retraction or discharge.
CLICK HERE FOR MORE HEALTH STORIES
Male breast cancer is rare, accounting for less than 1% of all cases globally. Because routine screenings like mammograms are not standard practice for men, the disease is often caught much later than it is in women.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Mane highlighted this issue as a primary motivation for speaking out. “Because it’s rarely talked about, it’s usually found at later stages and has worse outcomes,” he said. “I want to change that.”
Experts say the most common symptom of male breast cancer is a hard, painless lump located directly behind or near the nipple. (Dimitrios Kambouris/Getty Images)
Medical data supports Mane’s concerns regarding late-stage detection. While male breast cancer can occur at any age, it is most frequently diagnosed in older men, according to Mayo Clinic.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Men’s treatment plans generally mirror those for women, typically involving surgery to remove the breast tissue, followed by chemotherapy, radiation or hormone therapy depending on how far the cancer has progressed.
Treatment plans generally mirror those for women, typically involving surgery to remove the breast tissue, followed by chemotherapy, radiation or hormone therapy depending on how far the cancer has progressed. (Rune Hellestad/Corbis via Getty Images)
Mane said he is utilizing his platform to normalize conversations about male health and encourage early detection. He concluded his video by asking his followers to spread the word and help educate others.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“Follow, like and share, and come along for my journey to kick this thing in the ass,” Mane said. “Send this to 10 of your friends and have them follow me, because people need to hear this.”
Health
New York anchor Bill Ritter announces Alzheimer’s diagnosis during his final Eyewitness News broadcast
Ultra-processed foods linked to dementia risk
Amen Clinics Associate Medical Director Dr. Eboni Cornish joins ‘Fox & Friends First’ to discuss a study revealing a 58% higher dementia risk and 46% increase in cognitive impairment from consuming ultra-processed foods.
NEWYou can now listen to Fox News articles!
Veteran New York news anchor Bill Ritter revealed Friday that he has been diagnosed with early-stage Alzheimer’s disease, bringing an end to his more than two-decade run behind the WABC-TV anchor desk.
Ritter, 76, who has anchored the station’s 6 p.m. newscast in New York City since 2001, revealed during Friday’s Eyewitness News broadcast that it would be his final night anchoring the program.
“After a series of tests, my doctors have told me I have Alzheimer’s,” Ritter said during the broadcast.
“It’s early-stage Alzheimer’s, and they say the treatments I’m getting are keeping it at bay, for now,” he continued. “But there is no guarantee, because there’s no cure yet for Alzheimer’s.”
‘DUCK DYNASTY’ STAR PHIL ROBERTSON DIAGNOSED WITH ALZHEIMER’S DISEASE
Veteran New York news anchor Bill Ritter announced that he has been diagnosed with early-stage Alzheimer’s disease and is stepping away from the WABC-TV anchor desk. (Linda Rosier/NY Daily News Archive via Getty Images)
“So, unless someone finds an amazing cure, and soon, tonight will be the last newscast I anchor,” he added.
According to ABC7, Ritter joined WABC-TV in 1998 after an extensive journalism career that included work at the Los Angeles Times, local television stations in California and positions with ABC News.
He began anchoring the station’s 11 p.m. Eyewitness News broadcast in 1999 and was added to the flagship 6 p.m. newscast in 2001. He also anchored the station’s 5 p.m. broadcast for several years.
WOMAN WITH ADVANCED ALZHEIMER’S REGAINED SPEECH AND MEMORIES AFTER TAKING MAGIC MUSHROOMS
Bill Ritter has anchored WABC-TV’s 6 p.m. newscast in New York City since 2001. (Heidi Gutman/Disney via Getty Images)
ABC7 reported that Ritter will remain with the station in a new role focused in part on reporting about Alzheimer’s disease and other neurological conditions, as well as their impact on patients and families.
“For decades, Bill Ritter has covered and led New Yorkers through the stories that matter most,” WABC-TV General Manager Marilu Galvez said in a statement.
“A defining presence at ABC7, he has done so with exceptional insight, integrity and, most of all, heart, earning the love and respect of viewers and colleagues alike,” she continued.
“While he is stepping away from daily anchoring, he will continue to be an integral part of our ABC7 family, including sharing personal updates and providing resources to help others impacted by Alzheimer’s better understand the disease and the resources available to them.”
EXPERIMENTAL ALZHEIMER’S DRUG COULD REDUCE ALCOHOL WITHDRAWAL DAMAGE, RESEARCHERS SAY
Bill Ritter, Eyewitness News Anchor, WABC-TV, speaks onstage at the ROAR Forward Summit at Hearst Tower on November 19, 2024 in New York City. (Craig Barritt/Getty Images for Hearst)
“Bill is strong, brilliant, and resourceful, and we look forward to his continued reporting on Eyewitness News,” Galvez added.
New York City Mayor Zohran Mamdani responded to Ritter’s announcement by wishing the veteran broadcaster and his family “strength in the days ahead.”
“For decades, Bill Ritter has been a trusted presence in New Yorkers’ homes, helping us make sense of the news that shape our city,” Mamdani wrote on X. “
“His courage in sharing his Alzheimer’s diagnosis will help countless families facing the same challenge feel less alone,” he continued. “Wishing Bill, his loved ones, and everyone affected by Alzheimer’s strength in the days ahead.”
Ritter’s colleagues also reacted to his announcement.
ALZHEIMER’S RISK SLASHED BY EATING MORE OF ONE COMMON FOOD, STUDY SUGGESTS
WABC-TV reporter Lucy Yang paid tribute to Ritter’s professionalism and dedication during his decades-long career at the station.
“For decades, I’ve reported for his show and even filled in, anchored w him,” she posted on X. “He never gave less than 110% I salute you. I thank you. And I will pray for you.”
Lee Goldberg, the station’s chief meteorologist, said Ritter’s influence would continue long after he stepped away from the anchor desk.
“He preaches be kind, take care of each other, & we’re all in this together,” Goldberg said on X. “Now, in addition to doing these things for himself & his loving family, he’ll build on his legendary legacy by helping millions who share his battle.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“You’re a saint, and my hero @billritter7,” he added. “Love you.”
Ritter also noted during the broadcast that his father died from Alzheimer’s disease in 1998 after battling the illness for years.
-
New York20 minutes agoVideo: Fans Celebrate Knicks’ First N.B.A. Title in 53 Years
-
Los Angeles, Ca25 minutes agoKamala Harris surprises diners at The Abbey in West Hollywood
-
Detroit, MI47 minutes agoReview: Ambitious chef’s second restaurant brings promise to Midtown
-
San Francisco, CA55 minutes agoWhere to watch Chicago Cubs vs San Francisco Giants: TV channel, start time, streaming for June 14
-
Dallas, TX1 hour agoQuiet Cowboys free agent signing may not survive the summer
-
Miami, FL1 hour agoAuthorities searching for person who may have gone overboard in Biscayne Bay
-
Boston, MA1 hour ago
Where to watch Texas Rangers vs Boston Red Sox: TV channel, start time, streaming for June 14
-
Denver, CO1 hour ago‘Full send, full speed;’ Red Bull brings Soapbox racing back to Denver
